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Conclusions: Major bleeding is common after primary PCI for STEMI and associated
with increased mortality during 1 year follow-up. The CRUSADE bleeding risk score
underestimated the risk of major bleeding and therefore the use of this tool might be
limited in STEMI.
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Background: Red cell distribution width (RDW), a numerical measure of the variability
of the size of circulating erythrocytes, has been shown to be an independent predictor of
mortality in cardiovascular disease, and in patients undergoing PCI. The purpose of this
study was to determine if RDW is a prognostic marker of major post-PCI bleeding.
Methods: The study population included 4387 patients with coronary artery disease who
were subjected to PCI. The RDW was derived from a complete blood count (CBC) drawn
before PCI. Major bleeding was defined as hematocrit decrease15%, transfusion of2
units of packed red blood cells, gastrointestinal or intracerebral bleeding. Multivariable
logistic analysis of major in-hospital bleeding was performed using a logistic regression
model. Baseline characteristics associated with bleeding were included in the model.
Results: In 250 patients with a bleed, RDW was significantly higher than in the 4137
patients who did not bleed (14.4 	/ 2.1% vs 13.5 	/ 1.6%, p 0.001). On
multivariable analysis, after adjustment for known correlates of bleeding, RDW was a
significant predictor of bleeding (OR 1.14, 95% CI 1.05-1.23, p0.002). (Table 1)
Conclusions: RDW, an easily obtainable marker, has a strong independent linear
relationship with major post-procedure bleeding in patients undergoing PCI. These data
suggest that further investigation is necessary to determine the relationship of RDW and
bleeding post-PCI.
Independent Correlates of Major Bleeding Post PCI
Variable OR 95% CI p value
RDW 1.14 1.05–1.23 0.002
Male 0.47 0.34–0.64 0.001
BMI 0.97 0.94–1.0 0.021
IABP use 3.42 2.05–5.71 0.001
Cardiogenic Shock 2.28 1.2–4.34 0.012
Acute MI 2.19 1.42–3.38 0.001
Angiomax®(Bivalrudin) 0.53 0.37–0.77 0.001
Closure Device 0.66 0.48–0.90 0.01
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Background: Consensus guidelines recommend discontinuation of thienopyridine ther-
apy 5-7 days before planned coronary artery bypass graft (CABG) surgery to reduce
bleeding-related events. However, surgery is often performed within this time period to
reduce the risk of ischemic events. Evidence supporting the use of on-treatment platelet
reactivity testing before CABG is limited.
Methods: Patients undergoing CABG within 5 days of thienopyridine discontinuation
were prospectively enrolled from 08/2010 to 02/2012. On-treatment platelet reactivity
was measured with Verify Now (VN) P2Y12 assay, vasodilator stimulated phosphopro-
tein phosphorylation (VASP) and light transmittance aggregometry (LTA) with 5 and 20
M of ADP. The primary end point was in-hospital major bleeding (IHMB), defined as
bleeding intracranially, that associated with hemodynamic compromise, a hemoglobin
drop of 5 g/dl, or a hematocrit drop of 15%. The relation between platelet reactivity
value and IHMB was assessed with Wilcoxon rank-sum test; its relation with hematocrit
(Htc) drop was evaluated with Spearman correlation.
Results: The population consisted of 80 patients. IHMB occurred in 37 patients (46.3%).
VASP and LTA with 5 M or 20 M of ADP were associated with the primary endpoint
(IHMB). (Table) VN and VASP levels demonstrated an inverse correlation with the
degree of Htc drop after CABG (p0.002 and 0.041, respectively). A VASP platelet
reactivity index (PRI) of 50% is predictive of IHMB (p0.013), but a cut-off value of 230
P2Y12 reaction units (PRU) for VN is not (p0.26). Surgical related bleeding is not
predicted by platelet reactivity testing.
Major bleeding
present (Median [IQ
range])
Major bleeding
absent (Median [IQ
range]) p Value
Verify Now
(PRU)
198 [156–271] 221.5 [195–275] 0.093
VASP (PRI ) 55.2 [25–64] 62.5 [52.5–74.9] 0.004
LTA ADP 5M 39 [31.5–49] 49 [43–56] 0.002
LTA ADP 20M 48.5 [43–65.5] 65 [55–72] 0.002
Conclusions: On-treatment platelet reactivity testing with VASP or LTA 5 M or 20
M of ADP before CABG are able to predict the occurrence IHMB. A VASP PRI value
of 50% may indicate the need to postpone surgery for patients undergoing CABG
within 5 days of thienopyridine discontinuation.
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Background: Coronary no reflow is infrequent complications during percutanous
coronary intervention (PCI), however its impact on long term clinical outcome is not well
studied.
Methods: A total 1926 all comer patients (pts) including acute myocardial infarction
(MI) pts who underwent PCI with DESs were enrolled for this study. Study population
was divided into two groups; no reflow group (n50 pts) and non no reflow group
(n1876 pts). Angiographic at 6 months and clinical outcomes up to 24 months were
compared between the two groups.
Results: Baseline characteristics were similar between the two groups. The incidence of
angiographic no-reflow was in 2.6% (50/1926). At 6 months, no-reflow group had more
incidences of higher late loss. At 24 months clinical follow up, the no-reflow group had
worse clinical outcomes including higher cumulative incidence of total death, Q-MI and
major adverse cardiac events (MACEs, Table).
Conclusions: In the current study, despite of low incidence of no-reflow in general PCI
population, those patients had worse angiographic and clinical outcomes up to 24 months.
Special care should be exercised in this particular subset of pts during and after the
procedure.
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Background: Little evidence exists to guide risk stratification and management of
patients with prior coronary artery stenting who require noncardiac surgery. While clinical
models for perioperative risk stratification have been established, few studies have
examined angiographic contributors to perioperative risk.
Methods: We examined 405 patients with prior coronary artery stenting who underwent
non-cardiac surgery between 8/23/2001 and 12/27/2009 at a tertiary care institution for
whom detailed information on coronary anatomy and perioperative treatment could be
obtained. Coronary angiograms were independently reviewed, and patients were followed
for a median of 3.1 years after surgery.
Results: In our study population, 52% had prior MI, 18% had prior stroke/TIA, and 26%
had prior heart failure. The median time from PCI to surgery was 325 days (interquartile
range [IQR] 81 to 808). Among these patients, 35% were stented electively, 14% were
stented in the STEMI setting, and 51% were stented in the NSTE ACS setting. Lesions
treated included 18 previously stented lesions, 83 bifurcation lesions, 117 highly calcified
lesions, and 53 lesions with visible thrombus. A total of 188 patients (46%) were treated
with 1 stent, with a median stent diameter of 3mm (IQR 2.5-3) and a median stent
length of 18 mm (IQR 13 to 23). A total of 243 patients (60%) were stented with1 drug
eluting stent (DES). At the time of surgery, 125/220 (57%) patients still on clopidogrel
stopped clopidogrel at a median of 8 days (IQR 5-11) prior to surgery. Among 116 DES
patients undergoing surgery within a year of stent implantation, 37 (32%) stopped
clopidogrel prior to surgery, and 12 (10%) were bridged with a parenteral antithrombotic
agent. Perioperative MI occurred in 19 patients (4.7%). Perioperative bleeding defined as
a preoperative to nadir hematocrit difference 10% occurred in 114 patients (28%) and
transfusions were given in 65 patients (16%). The 3-year mortality risk was 17%.
Conclusions: Patients with coronary disease undergoing noncardiac surgery remain a
high risk population for whom evidence-based strategies are greatly needed to improve
perioperative outcomes.
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Background: Gastrointestinal bleeding (GIB) remains a serious complication for
patients undergoing percutaneous coronary intervention (PCI). Little is known about the
resource utilization and cost for patients with GI bleeding following PCI. We sought to
analyze healthcare resource utilization, cost, and mortality during the study period from
1998-2006 for patients with post-PCI GI bleed.
Methods: The Nationwide Inpatient Sample (NIS), which contains over a hundred
clinical and nonclinical data elements, was analyzed from 1998 to 2006. The primary
analysis was to assess the added hospitalization cost for PCI associated GIB over the study
period. The secondary analysis looked at resource utilization of PCI associated GIB. GIB
was defined as any active bleeding from the upper or lower GI tract. Multivariate linear
regression model was used to adjust for baseline procedure variables. All tests were
2-tailed, with p0.05 considered significant.
Results: There were 1,204.065 patients without GIB and 12,694 (1.04%) with post-PCI
GIB. Post-PCI GIB was associated with increased average hospital cost ($60,094 vs.
$36,758, p0.001) over the study period and increased mortality (6.0% vs. 0.76%,
p0.001) when compared to PCI without GIB. The overall cost increased for both groups
during the study period (p for trend0.001) due to increasing cost of PCI (p0.0001).
The added cost for patients that suffered GIB ($23,336) was secondary to increased need
for blood product administration; FFP ($10,045) and PRBC ($4110), both p0.0001),
and pulmonary artery catheterization ($ 8,612) (p0.0001). Upper and lower endoscopy
did not significantly add to cost for patients with GIB (p0.91).
Conclusions: The overall cost of PCI increased over the study period. PCI-associated
GIB is associated with higher mortality. Incremental costs of GIB are due to blood product
administration and expense associated with hemodynamic monitoring.
Year Cost
No GIB (N) GIB (N)
1998 $23931 (93928) $40790 (931)
1999 $25603 (97027) $43775 (1074)
2000 $27360 (114503) $46705 (1264)
2001 $28519 (137127) $48491 (1568)
2002 $33627 (141957) $56674 (1610)
2003 $38947 (138266) $63707 (1598)
2004 $44101 144479) $70162 (1515)
2005 $47659 (150043) $78981 (1418)
2006 $48197 (169440) $78911 (1505)
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Background: To evaluate the clinical safety and effectiveness of the DESolve™
Myolimus-Eluting Bioresorbable Coronary Scaffold (BCSS)in patients with single de
novo native coronary artery lesions through clinical endpoints and multiple imaging
modalities. The DESolve BCSS is a novel drug eluting device that combines a
PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug
Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor has demonstrated potent
anti-proliferative properties in two First-in-Man (FIM) trials using Elixir’s metallic
Myolimus-eluting coronary stents. Drug dose is 3 mcg per mm of scaffold length; the
same dose used in the FIM studies.
Methods: Sixteen patients with single, de novo coronary artery lesions were enrolled in
this prospective, multi-center, single-arm FIM study. One patient did not receive a study
stent and was deregistered. The 15 remaining patients are being analysed for multiple
clinical endpoints: Device and Procedure Success; Major Adverse Cardiac Events
(MACE), a composite endpoint of cardiac death, target vessel MI, and clinically-indicated
target lesion revascularization (CI-TLR); clinically-indicated Target Lesion and Target
Vessel Revascularization, (CI-TVR) and stent thrombosis assessed at 1, 6 and 12 months
and annually to 5 years. Multiple assessments by angiographic, IVUS and OCT at 6
months were completed. An additional analysis using multislice computed tomography
(MSCT) will be completed at 12 and 24 months.
Results: At 6 months, the in-scaffold late lumen loss was 0.19  0.19 by QCA, the %
volume obstruction was 7.18 3.37 by IVUS, and by OCT 98.68 2.44% of struts were
demonstrated as covered. There was one MACE event, a TLR, during the follow-up
period. Detailed clinical and imaging results through 6 months will be presented.
Conclusions: The DESolve™ Myolimus-Eluting BCSS demonstrated both excellent
safety and effectiveness in this FIM study, thus warranting further clinical evaluation of
the novel technology in larger clinical studies. Detailed clinical and imaging results
through 6 months will be presented.
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